At AstraZeneca PLC, I was the Medical Science Director for AstraZeneca’s Boston site, responsible for the medical and clinical aspects of development of agents from chemical lead identification through clinical proof of concept in phase II. I was responsible for the design and interpretation of the entire clinical development plan for five agents. This position had global responsibilities with clinical trials in the US, Canada, European Union, Japan and Korea. I was a member of the Strategic Planning & Business Development as an ad hoc member and was the global Disease Area Clinical Expert for Hematology.